Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results

      ZIMMER BIOMET INC. LOGO

      News provided by

      Zimmer Biomet Holdings, Inc.

      Jul 30, 2015, 07:30 ET

      Share this article

      Share this article


      WARSAW, Ind., July 30, 2015 /PRNewswire/ --

      • Net Sales of $1.17 billion represent a decrease of 1.3% reported from the prior year period and an increase of 5.7% constant currency
      • Reported net loss per share for the second quarter was $(0.91), and adjusted earnings per share were $1.59, an increase of 0.6% over the prior year period
      • Company updates guidance

      Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2015.  The Company reported second quarter net sales of $1.17 billion, a decrease of 1.3% reported and an increase of 5.7% constant currency compared to the second quarter of 2014.  Acquired revenue from Biomet amounted to $60 million, a contribution of 5.0% of the constant currency growth rate.  Standalone Zimmer recorded constant currency growth in the quarter of 0.7%.  Reported net loss per share for the quarter was $(0.91) and adjusted earnings per share were $1.59, an increase of 0.6% over the prior year period.

      "During the quarter, we completed our landmark combination to create Zimmer Biomet, marking a new era for our company and an unprecedented opportunity to drive our growth and value creation strategies," said David Dvorak, President and CEO of Zimmer Biomet.  "With a broad and diversified musculoskeletal portfolio, Zimmer Biomet is well positioned to reach new heights of commercial and operational excellence, and to accelerate the pace of our innovation for the evolving healthcare landscape."

      Net loss for the second quarter was $(158.0) million on a reported basis.  On an adjusted basis, net earnings increased 2.8% over the prior year period, to $278.7 million.  Operating cash flow for the second quarter was $186.8 million. 

      During the quarter, the Company recorded certain non-recurring, pre-tax expenses, including $465.0 million of charges relating to the Biomet merger and $89.6 million of special items and certain claims.  Additionally, pre-tax amortization expense in the quarter was $34.9 million.

      Also in the quarter, the Company paid $37.4 million in dividends and declared a second quarter dividend of $0.22 per share, consistent with the dividend declared for the prior year period.

      Guidance

      The Company updated its full-year 2015 reported sales and adjusted earnings per share guidance, and reaffirmed constant currency sales growth for 2015 for the combined entity.  Full-year 2015 constant currency revenue, compared to pro forma 2014 revenue, is still expected to increase between 1.5% and 2.0%.  The pro forma adjustments to the prior year reflect the inclusion of Biomet revenue for the comparable post-merger closing period in the prior year and the impact of the previously announced divestiture remedies.  The Company expects foreign currency translation to decrease revenues approximately 6.0% for the full year, resulting in reported revenue decreasing between 4.0% and 4.5% when compared to pro forma 2014 revenue. 

      The Company now expects full-year 2015 diluted earnings per share to be in a range of $6.65 to $6.80 on an adjusted basis.  Previously, the Company estimated fully diluted adjusted earnings per share to be in a range of $6.60 to $6.80.  The Company also continues to project $350 million in pre-tax, net synergies by the end of the third year following the merger closing.  Additionally, within the first twelve months post-closing, the Company continues to expect to realize earnings per share accretion in a range of $0.95 to $1.05 relating to the Biomet merger, with $135 million of pre-tax, net synergy savings.

      Conference Call

      The Company will conduct its second quarter 2015 investor conference call today, July 30, 2015, at 8:00 a.m. Eastern Time.  The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at http://investor.zimmerbiomet.com.  It will be archived for replay following the conference call.

      Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (877) 941-1227 and entering conference ID 4696682.  For a complete listing of international toll-free and local numbers, please visit http://investor.zimmerbiomet.com.  A digital recording will be available 24 hours after the completion of the conference call, from August 1, 2015 to August 30, 2015.  To access the recording, U.S. and Canada callers should dial (800) 406-7325 and international callers should dial +1 (303) 590-3030, and enter the Access Code ID 4696670.

      Sales Tables

      The following sales tables provide results by geographic segment and product category, as well as the percentage change compared to the prior year quarter and six months, on both a reported and constant currency basis.

      NET SALES - THREE MONTHS ENDED  JUNE 30, 2015


      (in millions, unaudited)




































      Constant





      Net


      Reported


      Currency





      Sales


       % Change


      % Change

      Zimmer











      Geographic Segments












      Americas

      $

      638



      (0.2)

      %


      0.4

      %



      EMEA


      277



      (17.2)



      (0.2)




      Asia Pacific


      193



      (7.7)



      2.8





      Total Zimmer


      1,108



      (6.4)



      0.7















      Biomet



      60



      -



      -















      Zimmer Biomet


      $  1,168



      (1.3)



      5.7















      Zimmer











      Product Categories












      Reconstructive












         Americas


      $     472



      (0.2)



      0.4




         EMEA


      217



      (16.8)



      0.6




         Asia Pacific


      143



      (8.8)



      2.0

















             Total


      832



      (6.6)



      0.7


















      Knees













         Americas


      290



      2.8



      3.3





         EMEA


      109



      (17.8)



      (0.6)





         Asia Pacific


      77



      (7.5)



      3.7


















             Total


      476



      (4.4)



      2.3


















      Hips













         Americas


      146



      (4.2)



      (3.4)





         EMEA


      98



      (16.3)



      1.4





         Asia Pacific


      63



      (11.4)



      (1.2)


















             Total


      307



      (9.9)



      (1.3)


















      Extremities


      49



      (5.9)



      (1.0)

















      Dental


      57



      (6.8)



      -

















      Trauma


      73



      (7.9)



      (0.7)

















      Spine


      52



      (0.2)



      4.7

















      Surgical and other


      94



      (6.1)



      (0.6)


















      Total Zimmer


      1,108



      (6.4)



      0.7















      Biomet



      60



      -



      -















      Zimmer Biomet


      $  1,168



      (1.3)



      5.7















      NET SALES - SIX MONTHS ENDED JUNE 30, 2015


      (in millions, unaudited)




































      Constant





      Net


      Reported


      Currency





      Sales


       % Change


      % Change

      Zimmer











      Geographic Segments












      Americas


      $  1,283



      0.4

      %


      1.0

      %



      EMEA


      576



      (12.9)



      4.2




      Asia Pacific


      383



      (5.3)



      4.8





      Total Zimmer


      2,242



      (4.4)



      2.6















      Biomet



      60



      -



      -















      Zimmer Biomet


      $  2,302



      (1.8)



      5.1















      Zimmer











      Product Categories












      Reconstructive












         Americas


      $     950



      0.5



      1.0




         EMEA


      451



      (12.7)



      4.9




         Asia Pacific


      282



      (5.9)



      4.5

















             Total


      1,683



      (4.5)



      2.8


















      Knees













         Americas


      585



      3.4



      4.0





         EMEA


      230



      (12.9)



      4.4





         Asia Pacific


      148



      (5.3)



      5.2


















             Total


      963



      (2.3)



      4.3


















      Hips













         Americas


      292



      (3.8)



      (3.1)





         EMEA


      202



      (13.3)



      4.6





         Asia Pacific


      126



      (7.7)



      2.5


















             Total


      620



      (7.9)



      0.7













      -





      Extremities


      100



      (2.9)



      1.9

















      Dental


      113



      (7.7)



      (1.3)

















      Trauma


      152



      (4.1)



      3.0

















      Spine


      102



      1.1



      6.0

















      Surgical and other


      192



      (4.4)



      1.2


















      Total Zimmer


      2,242



      (4.4)



      2.6















      Biomet



      60



      -



      -















      Zimmer Biomet


      $  2,302



      (1.8)



      5.1


      About the Company

      Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare.  We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

      We collaborate with healthcare professionals around the globe to advance the pace of innovation.  Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues.  Together with healthcare professionals, we help millions of people live better lives.

      We have operations in more than 25 countries around the world and sell products in more than 100 countries.  For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmer.

      Website Information

      We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

      Note on Non-GAAP Financial Measures

      As used in this press release, the term "adjusted" refers to operating performance measures that exclude inventory step-up and other inventory and manufacturing related charges, certain claims, special items, intangible asset amortization, financing and other expenses related to the Biomet merger and certain tax adjustments.  Included in special items are acquisition and integration costs and asset impairment charges related to acquisitions, as well as employee termination benefits, consulting and professional fees, certain litigation matters, dedicated personnel expenses, certain contract terminations and asset impairment charges connected with global restructuring and operational excellence initiatives.  The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates.  Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.

      Beginning with the three months ended March 31, 2015, we have changed our quarter-end closing convention for the majority of our international reporting units.  As a consequence, our results of operations for the six months ended June 30, 2015 include up to four more billing days for such international reporting units than were included in our results of operations for the six months ended June 30, 2014.  We have not restated the presentation of our 2014 financial statements to conform to this change of closing convention because the impact of the change is not material to the results of operations or to the comparisons between the 2015 and 2014 periods.

      Cautionary Statement Regarding Forward-Looking Statements

      This communication contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology.  Such forward-looking statements include, but are not limited to, statements about the benefits of the merger between Zimmer and LVB Acquisition, Inc. ("LVB"), the parent company of Biomet, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  These risks and uncertainties include, but are not limited to: the possibility that the anticipated synergies and other benefits from the merger will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of the legacy companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to the merger; the effect of the merger on our relationships with customers, vendors and lenders and on our operating results and businesses generally; Biomet's compliance with its Deferred Prosecution Agreement through March 2016; the outcome of government investigations; price and product competition; the success of our quality and operational excellence initiatives; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures, including the impact of the U.S. excise tax on medical devices; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; the ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations, including regulations of the U.S. Food and Drug Administration (the "FDA") and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing economic uncertainty affecting countries in the Euro zone on the ability to collect accounts receivable in affected countries.  For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC").  Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.zimmerbiomet.com or on request from us.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this communication.


       ZIMMER BIOMET HOLDINGS, INC. 

       CONSOLIDATED STATEMENTS OF EARNINGS 

       FOR THE THREE MONTHS ENDED JUNE 30, 2015 and 2014 

       (in millions, except per share amounts, unaudited) 







      2015


      2014


       Net Sales 

      $     1,167.6


      $     1,182.9


       Cost of products sold 

      290.5


      331.6


       Gross Profit 

      877.1


      851.3







       Research and development 

      51.4


      48.0


       Selling, general and administrative 

      445.1


      436.1


       Certain claims 

      7.7


      21.8


       Intangible asset amortization 

      33.0


      22.2


       Special items 

      469.4


      62.3


            Operating expenses 

      1,006.6


      590.4







       Operating Profit 

      (129.5)


      260.9


       Other expense, net 

      (4.0)


      (11.6)


       Interest income 

      2.5


      2.9


       Interest expense 

      (82.7)


      (15.8)


       Earnings before income taxes  

      (213.7)


      236.4


       Provision for income taxes 

      (55.5)


      60.3


       Net (loss) earnings 

      (158.2)


      176.1


       Less:  Net loss attributable to noncontrolling interest 

      (0.2)


      (0.4)


       Net (Loss) Earnings of Zimmer Biomet Holdings, Inc. 

      $      (158.0)


      $        176.5







       (Loss) Earnings Per Common Share 





           Basic 

      $        (0.91)


      $          1.05


           Diluted 

      $        (0.91)


      $          1.03







       Weighted Average Common Shares Outstanding 





           Basic 

      173.0


      168.4


           Diluted 

      173.0


      171.0







       Cash dividends declared per common share 

      $          0.22


      $          0.22



       ZIMMER BIOMET HOLDINGS, INC. 

       CONSOLIDATED STATEMENTS OF EARNINGS 

       FOR THE SIX MONTHS ENDED JUNE 30, 2015 and 2014 

       (in millions, except per share amounts, unaudited) 







      2015


      2014


       Net Sales 

      $     2,302.0


      $     2,344.4


       Cost of products sold 

      569.2


      635.3


       Gross Profit 

      1,732.8


      1,709.1







       Research and development 

      99.8


      95.4


       Selling, general and administrative 

      870.1


      880.6


       Certain claims 

      7.7


      21.8


       Intangible asset amortization 

      53.4


      51.4


       Special items 

      556.4


      98.9


            Operating expenses 

      1,587.4


      1,148.1







       Operating Profit 

      145.4


      561.0


       Other expense, net 

      (26.6)


      (13.3)


       Interest income 

      5.1


      5.4


       Interest expense 

      (105.8)


      (30.8)


       Earnings before income taxes  

      18.1


      522.3


       Provision for income taxes 

      (0.5)


      125.1


       Net earnings 

      18.6


      397.2


       Less:  Net loss attributable to noncontrolling interest 

      (0.5)


      (0.8)


       Net Earnings of Zimmer Biomet Holdings, Inc. 

      $          19.1


      $        398.0







       Earnings Per Common Share 





             Basic 

      $          0.11


      $          2.36


             Diluted 

      $          0.11


      $          2.32







       Weighted Average Common Shares Outstanding 





           Basic 

      171.5


      168.7


           Diluted 

      174.2


      171.4







       Cash dividends declared per common share 

      $          0.44


      $          0.44


       ZIMMER BIOMET HOLDINGS, INC. 

       CONDENSED CONSOLIDATED BALANCE SHEETS 

       (in millions, unaudited) 






      June 30,

      December 31,





      2015

      2014

       Assets 






       Current Assets: 






         Cash and cash equivalents 




      $            1,424.6

      $            1,083.3

         Short-term investments 




      459.0

      612.5

         Receivables, net 




      1,490.3

      912.1

         Inventories 




      2,441.4

      1,169.0

         Other current assets 




      936.2

      512.1

             Total current assets 




      6,751.5

      4,289.0







       Property, plant and equipment, net 



      1,998.6

      1,288.8

       Goodwill 




      7,730.7

      2,514.2

       Intangible assets, net 




      9,941.5

      603.5

       Other assets 




      781.7

      939.2

       Total Assets 




      $          27,204.0

      $            9,634.7







       Liabilities and Stockholders' Equity 











       Other current liabilities 




      $            1,863.1

      $            1,038.0

       Current portion of long-term debt 



      300.0

      -

       Other long-term liabilities 




      3,165.2

      648.6

       Long-term debt 




      11,749.8

      1,425.5

       Stockholders' equity 




      10,125.9

      6,522.6

       Total Liabilities and Stockholders' Equity 


      $          27,204.0

      $            9,634.7

       ZIMMER BIOMET HOLDINGS, INC. 

       CONSOLIDATED STATEMENTS OF CASH FLOWS 

       FOR THE SIX MONTHS ENDED JUNE 30, 2015 and 2014 

       (in millions, unaudited) 













      2015

      2014








       Cash flows provided by (used in) operating activities 





       Net earnings 




      $          18.6

      $        397.2


       Depreciation and amortization 




      188.6

      192.3


       Share-based compensation 




      185.3

      24.2


       Income tax benefits from employee stock compensation plans 


      74.0

      28.8


       Excess income tax benefits from employee stock compensation plans 


      (9.1)

      (8.6)


       Inventory step-up 




      10.5

      4.2


       Gain on divestiture of assets 




      (18.9)

      -


       Changes in operating assets and liabilities, net of acquired assets and liabilities 




           Income taxes 




      30.5

      (114.4)


           Receivables 




      (59.3)

      (14.7)


           Inventories 




      (149.9)

      (85.2)


           Accounts payable and accrued expenses 



      95.8

      (1.7)


           Other assets and liabilities 




      (87.8)

      20.8


       Net cash provided by operating activities 



      278.3

      442.9








       Cash flows provided by (used in) investing activities 





       Additions to instruments 




      (104.0)

      (112.0)


       Additions to other property, plant and equipment 


      (64.8)

      (63.4)


       Purchases of investments 




      (152.6)

      (783.3)


       Sales of investments 




      398.9

      691.4


       Proceeds from divestiture of assets 



      24.1

      -


       Biomet acquisition, net of acquired cash 



      (7,812.9)

      -


       Investments in other assets 




      (9.4)

      (1.4)


       Net cash used in investing activities 



      (7,720.7)

      (268.7)








       Cash flows provided by (used in) financing activities 





       Proceeds from senior notes 




      7,628.2

      -


       Proceeds from term loan 




      3,000.0

      -


       Payments on senior notes 




      (2,740.0)

      -


       Net proceeds under revolving credit facilities 



      0.9

      0.5


       Dividends paid to stockholders 



      (74.7)

      (70.9)


       Proceeds from employee stock compensation plans 


      34.6

      218.9


       Excess income tax benefits from employee stock compensation plans 


      9.1

      8.6


       Debt issuance costs 




      (58.4)

      (47.7)


       Repurchase of common stock 




      -

      (400.5)


       Net cash provided by (used in) financing activities 


      7,799.7

      (291.1)








       Effect of exchange rates on cash and cash equivalents 


      (16.0)

      5.0









       Increase (decrease) in cash and cash equivalents 


      341.3

      (111.9)

       Cash and cash equivalents, beginning of period 



      1,083.3

      1,080.6

       Cash and cash equivalents, end of period 



      $     1,424.6

      $        968.7

       ZIMMER BIOMET HOLDINGS, INC. 

       NET SALES BY GEOGRAPHIC SEGMENT 

       FOR THE THREE and SIX MONTHS ENDED JUNE 30, 2015 and 2014 

       (in millions, unaudited) 





       Three Months Ended June 30, 


       Six Months Ended June 30, 












      2015

      2014

      % (Dec)


      2015

      2014

      % Inc/(Dec)


       Zimmer 










       Americas 

      $        638.1

      $        639.7

      (0.2)

      %

      $     1,283.3

      $     1,278.4

      0.4

      %


       EMEA 

      277.0

      334.7

      (17.2)


      575.9

      661.6

      (12.9)



       Asia Pacific 

      192.6

      208.5

      (7.7)


      382.9

      404.4

      (5.3)




       Total Zimmer 

      1,107.7

      1,182.9

      (6.4)


      2,242.1

      2,344.4

      (4.4)














       Biomet 

      59.9

      -

      -


      59.9

      -

      -


       Zimmer Biomet 

      $     1,167.6

      $     1,182.9

      (1.3)


      $     2,302.0

      $     2,344.4

      (1.8)






































       ZIMMER BIOMET HOLDINGS, INC. 

       NET SALES BY PRODUCT CATEGORY 

       FOR THE THREE and SIX MONTHS ENDED JUNE 30, 2015 and 2014 

       (in millions, unaudited) 





       Three Months Ended June 30, 


       Six Months Ended June 30, 












      2015

      2014

      % (Dec)


      2015

      2014

      % Inc/(Dec)














       Zimmer 










       Reconstructive 











       Knees 

      $        475.8

      $        497.9

      (4.4)

      %

      $        963.1

      $        985.8

      (2.3)

      %



       Hips 

      307.4

      341.0

      (9.9)


      619.6

      672.7

      (7.9)




       Extremities 

      48.5

      51.5

      (5.9)


      100.7

      103.6

      (2.9)






      831.7

      890.4

      (6.6)


      1,683.4

      1,762.1

      (4.5)















       Dental 

      56.8

      61.1

      (6.8)


      112.6

      122.1

      (7.7)



       Trauma 

      72.6

      78.8

      (7.9)


      152.0

      158.5

      (4.1)



       Spine 

      52.2

      52.2

      (0.2)


      101.7

      100.5

      1.1



       Surgical and other 

      94.4

      100.4

      (6.1)


      192.4

      201.2

      (4.4)




       Total Zimmer 

      1,107.7

      1,182.9

      (6.4)


      2,242.1

      2,344.4

      (4.4)














       Biomet 

      59.9

      -

      -


      59.9

      -

      -


       Zimmer Biomet 

      $     1,167.6

      $     1,182.9

      (1.3)


      $     2,302.0

      $     2,344.4

      (1.8)


      ZIMMER BIOMET HOLDINGS, INC.

      RECONCILIATION OF REPORTED % GROWTH TO

      CONSTANT CURRENCY % GROWTH

      (unaudited)

























      For the Three Months Ended






      June 30, 2015









      Foreign


      Constant






      Reported


      Exchange


      Currency






      % Change


      Impact


      % Change

      Zimmer











      Geographic Segments












      Americas


      (0.2)

      %


      (0.6)

      %


      0.4

      %



      EMEA


      (17.2)



      (17.0)



      (0.2)




      Asia Pacific


      (7.7)



      (10.5)



      2.8





      Total Zimmer


      (6.4)



      (7.1)



      0.7















      Biomet



      -



      -



      -















      Zimmer Biomet


      (1.3)



      (7.0)



      5.7















      Zimmer











      Product Categories












      Reconstructive












         Americas


      (0.2)



      (0.6)



      0.4




         EMEA


      (16.8)



      (17.4)



      0.6




         Asia Pacific


      (8.8)



      (10.8)



      2.0

















             Total


      (6.6)



      (7.3)



      0.7







      -



      -



      -





      Knees













         Americas


      2.8



      (0.5)



      3.3





         EMEA


      (17.8)



      (17.2)



      (0.6)





         Asia Pacific


      (7.5)



      (11.2)



      3.7


















             Total


      (4.4)



      (6.7)



      2.3


















      Hips













         Americas


      (4.2)



      (0.8)



      (3.4)





         EMEA


      (16.3)



      (17.7)



      1.4





         Asia Pacific


      (11.4)



      (10.2)



      (1.2)


















             Total


      (9.9)



      (8.6)



      (1.3)


















      Extremities


      (5.9)



      (4.9)



      (1.0)

















      Dental


      (6.8)



      (6.8)



      -

















      Trauma


      (7.9)



      (7.2)



      (0.7)

















      Spine


      (0.2)



      (4.9)



      4.7

















      Surgical and other


      (6.1)



      (5.5)



      (0.6)


















      Total Zimmer


      (6.4)



      (7.1)



      0.7















      Biomet



      -



      -



      -















      Zimmer Biomet


      (1.3)



      (7.0)



      5.7


      ZIMMER BIOMET HOLDINGS, INC.

      RECONCILIATION OF REPORTED % GROWTH TO

      CONSTANT CURRENCY % GROWTH

      (unaudited)

























      For the Six Months Ended






      June 30, 2015









      Foreign


      Constant






      Reported


      Exchange


      Currency






      % Change


      Impact


      % Change

      Zimmer











      Geographic Segments












      Americas


      0.4

      %


      (0.6)

      %


      1.0

      %



      EMEA


      (12.9)



      (17.1)



      4.2




      Asia Pacific


      (5.3)



      (10.1)



      4.8





      Total Zimmer


      (4.4)



      (7.0)



      2.6















      Biomet



      -



      -



      -















      Zimmer Biomet


      (1.8)



      (6.9)



      5.1















      Zimmer











      Product Categories












      Reconstructive












         Americas


      0.5



      (0.5)



      1.0




         EMEA


      (12.7)



      (17.6)



      4.9




         Asia Pacific


      (5.9)



      (10.4)



      4.5

















             Total


      (4.5)



      (7.3)



      2.8







      -



      -



      -





      Knees













         Americas


      3.4



      (0.6)



      4.0





         EMEA


      (12.9)



      (17.3)



      4.4





         Asia Pacific


      (5.3)



      (10.5)



      5.2


















             Total


      (2.3)



      (6.6)



      4.3


















      Hips













         Americas


      (3.8)



      (0.7)



      (3.1)





         EMEA


      (13.3)



      (17.9)



      4.6





         Asia Pacific


      (7.7)



      (10.2)



      2.5


















             Total


      (7.9)



      (8.6)



      0.7


















      Extremities


      (2.9)



      (4.8)



      1.9

















      Dental


      (7.7)



      (6.4)



      (1.3)

















      Trauma


      (4.1)



      (7.1)



      3.0

















      Spine


      1.1



      (4.9)



      6.0

















      Surgical and other


      (4.4)



      (5.6)



      1.2


















      Total Zimmer


      (4.4)



      (7.0)



      2.6















      Biomet



      -



      -



      -















      Zimmer Biomet


      (1.8)



      (6.9)



      5.1


       ZIMMER BIOMET HOLDINGS, INC. 

       Reconciliation of Net Earnings and Adjusted Net Earnings 

       For the Three Months Ended June 30, 2015 and 2014 

       (in millions, unaudited) 








       Three Months 



       Ended June 30 



      2015


      2014






       Net (Loss) Earnings of Zimmer Biomet Holdings, Inc. 

      $      (158.0)


      $       176.5

       Inventory step-up and other inventory  




          and manufacturing related charges 

      14.7


      13.5

       Certain claims 


      7.7


      21.8

       Intangible asset amortization 

      33.0


      22.2

       Special items 





          Biomet-merger related 

      390.6


      13.7

          Other special items 

      78.8


      48.6

       Biomet merger-related expenses in other expense 

      3.2


      10.0

       Interest expense on Biomet merger financing 

      61.5


      -

       Taxes on above items* 

      (152.8)


      (35.3)

       Adjusted Net Earnings 

      $       278.7


      $       271.0






       * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items 

          were incurred. 









       ZIMMER BIOMET HOLDINGS, INC. 

       Reconciliation of Net Earnings and Adjusted Net Earnings 

       For the Six Months Ended June 30, 2015 and 2014 

       (in millions, unaudited) 








       Six Months 



       Ended June 30 



      2015


      2014






       Net Earnings of Zimmer Biomet Holdings, Inc. 

      $         19.1


      $       398.0

       Inventory step-up and other inventory  




          and manufacturing related charges 

      18.6


      25.2

       Certain claims 


      7.7


      21.8

       Intangible asset amortization 

      53.4


      51.4

       Special items 





          Biomet-merger related 

      416.4


      13.7

          Other special items 

      140.0


      85.2

       Biomet merger-related expenses in other expense 

      22.7


      10.0

       Interest expense on Biomet merger financing 

      70.0


      -

       Taxes on above items* 

      (196.4)


      (59.8)

       Adjusted Net Earnings 

      $       551.5


      $       545.5






       ZIMMER BIOMET HOLDINGS, INC. 

       Reconciliation of Diluted EPS and Adjusted Diluted EPS 

       For the Three Months Ended June 30, 2015 and 2014 

       (unaudited) 






       Three Months 


       Ended June 30, 


      2015


      2014





       Diluted EPS 

      $        (0.91)


      $          1.03

       Inventory step-up and other inventory  




          and manufacturing related charges 

      0.08


      0.08

       Certain claims 

      0.04


      0.13

       Intangible asset amortization 

      0.19


      0.13

       Special items 




          Biomet-merger related 

      2.22


      0.08

          Other special items 

      0.45


      0.28

       Biomet merger-related expenses in other expense 

      0.02


      0.06

       Interest expense on Biomet merger financing 

      0.35


      -

       Taxes on above items* 

      (0.86)


      (0.21)

       Effect of dilutive shares assuming net earnings** 

      0.01


      -

       Adjusted Diluted EPS 

      $          1.59


      $          1.58





       * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items 

          were incurred. 








       ** Diluted share count used in Adjusted Diluted EPS: 




               Diluted shares 

      173.0



               Dilutive shares assuming net earnings 

      2.6



            Adjusted diluted shares 

      175.6











       ZIMMER BIOMET HOLDINGS, INC. 

       Reconciliation of Diluted EPS and Adjusted Diluted EPS 

       For the Six Months Ended June 30, 2015 and 2014 

       (unaudited) 






       Six Months 


       Ended June 30, 


      2015


      2014





       Diluted EPS 

      $          0.11


      $          2.32

       Inventory step-up and other inventory  




          and manufacturing related charges 

      0.11


      0.15

       Certain claims 

      0.04


      0.13

       Intangible asset amortization 

      0.31


      0.30

       Special items 




          Biomet-merger related 

      2.39


      0.08

          Other special items 

      0.81


      0.49

       Biomet merger-related expenses in other expense 

      0.13


      0.06

       Interest expense on Biomet merger financing 

      0.40


      -

       Taxes on above items* 

      (1.13)


      (0.35)

       Adjusted Diluted EPS 

      $          3.17


      $          3.18





       * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items 

          were incurred. 




      Logo - http://photos.prnewswire.com/prnh/20150624/225371LOGO

      SOURCE Zimmer Biomet Holdings, Inc.

      Modal title

      Also from this source

      Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London

      Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London

      Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...

      Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery

      Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery

      Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today will announce Surgeon-Guided Autonomy, a new technology category representing the company's...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      Conference Call Announcements

      Conference Call Announcements

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.